Amarin Technologies S.A. has a patent-protected, advanced matrix system based on technology for developing and manufacturing ultra thin patches with low irritation, optimum adhesive characteristics and an improved pharmakocinetic profile. The devices designed by our Company are of the drug-in-adhesive type and consist of transparent and flat units, which contain the active principles in a matrix composed of acrylic pressure-sensitive adhesives, and excipients such as permeation enhancers, co-solvents and antioxidants.

Transdermal delivery systems (TDS) are easy to administer by the patient. Current transdermal devices provide therapy for periods between one and seven days. The increase in the interval between doses favours patient compliance. Another advantage is the production of sustained and controllable levels of drug in the plasma, avoiding peaks and troughs reached with the oral or intravenous routes of administration, and thus, decreasing the risk of potential side effects or lack of activity.

The Company has also developed an "enhancer" technology applied on gels. The drug permeation using this technology has a performance superior to most of competitors.

TRANSDERMAL THERAPEUTIC SYSTEMS
Passive Delivery Sstems

BILAYER Type Patch, Drug in Adhesive Design



MATRIX Type Patch, Drug in Adhesive Design